Bristol-Myers Squibb (BMS) said the European Patent Office (EPO) upheld a decision with regard to the European composition of matter patent covering dasatinib, the active ingredient in BMS’s leukemia drug Sprycel.
The EPO upheld a decision that found the patent to be invalid.
“This decision does not impact our patents outside of the EU or other Sprycel-related patents,” said BMS.
“BMS has a long-standing heritage in oncology.
“Sprycel will continue to be a significant asset in our broad oncology portfolio and an important treatment option for patients living with chronic myeloid leukemia (CML).”